ArticleInternational journal of oncology2013
Bone formation induced by BMP-2 in human osteosarcoma cells.
Article in International journal of oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Pannexins in the musculoskeletal system: new targets for development and disease progression.Bone research · 2024Review
- Farnesyl diphosphate synthase promotes cell proliferation by regulating gene expression and alternative splicing profiles in HeLa cells.Oncology letters · 2023Article
- Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.Journal of clinical medicine · 2021Review
- Osteosarcoma tissue-engineered model challenges oxidative stress therapy revealing promoted cancer stem cell properties.Free radical biology & medicine · 2021Article
- RUNX2 as a promising therapeutic target for malignant tumors.Cancer management and research · 2021Review
- To B (Bone Morphogenic Protein-2) or Not to B (Bone Morphogenic Protein-2): Mesenchymal Stem Cells May Explain the Protein's Role in Osteosarcomagenesis.Frontiers in cell and developmental biology · 2021Review
- GWAS for Meat and Carcass Traits Using Imputed Sequence Level Genotypes in Pooled F2-Designs in Pigs.G3 (Bethesda, Md.) · 2019Article
- BMP-2 inhibits lung metastasis of osteosarcoma: an early investigation using an orthotopic model.OncoTargets and therapy · 2018Article
- Increased microRNA-93-5p inhibits osteogenic differentiation by targeting bone morphogenetic protein-2.PloS one · 2017Article
- Bone morphogenetic protein signaling in musculoskeletal cancer.Journal of cancer research and clinical oncology · 2016Review
- Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma.Cell death & disease · 2016Review
- Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.International journal of molecular sciences · 2016Review
- Renal Cancer Stem Cells: Characterization and Targeted Therapies.Stem cells international · 2016Review
- BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.Journal of cancer research and clinical oncology · 2015Article
- Associations of polymorphisms in the bone morphogenetic protein-2 gene with risk and prognosis of osteosarcoma in a Chinese population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Pituitary adenylate cyclase-activating polypeptide (PACAP) signalling enhances osteogenesis in UMR-106 cell line.Journal of molecular neuroscience : MN · 2014Article
- Roles of bone morphogenetic protein signaling in osteosarcoma.International orthopaedics · 2014Review
- Hyperoside, a flavonoid compound, inhibits proliferation and stimulates osteogenic differentiation of human osteosarcoma cells.PloS one · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Our previous studies demonstrated that BMP-2 inhibits the tumorigenicity of cancer stem cells identified as cells with high aldehyde dehydrogenase activity (ALDH(br) cells) from the human osteosarcoma cell line OS99-1. We further investigated whether BMP-2 is capable of inducing bone formation in OS99-1 cells. Flow cytometry sorting was used to isolate tumorigenic ALDH(br) and non-tumorigenic ALDH(lo) cells. qRT-PCR was used to quantify the gene expression. A xenograft model was used to verify the bone formation in vivo. There was significantly higher mRNA expression of BMPR1B and BMPR2 in ALDH(lo) cells compared with that in ALDH(br) cells and the BMPR1B expression in ALDH(lo) cells was ~8-fold higher compared to that in ALDHbr cells. BMP-2 was also found to induce higher transcription of osteogenic markers Runx-2, Osterix (Osx), alkaline phosphatase (ALP) and collagen type I in ALDH(lo) cells compared to ALDH(br) cells, which were mediated by the canonical Smad signaling pathway. In vivo, BMP-2 was identified to induce bone formation in both ALDH(br) and ALDH(lo) cells. All animals receiving 1 x 10()4 ALDH(lo) cells treated with 30 µg of BMP-2 per animal showed bone formation within 1-2 weeks after injection in mice. Bone formation induced by BMP-2 in ALDH(lo) cells showed significantly more bone mineral content compared to that in ALDH(br) cells. BMP-2 induces bone formation in heterogeneous osteosarcoma cells and BMP-2 may have a promising therapeutic role for treating human osteosarcoma by inducing differentiation along an osteogenic pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.